Novo Nordisk Sues Sanofi-Aventis Over Insulin Delivery Patents
Sanofi-Aventis’ handheld OptiClik is an insulin delivery device, or “insulin pen” for Type 1 and Type 2 diabetes. Novo Nordisk alleges the device infringes on of its patents, prompting the complaint filed in U.S. District Court for Delaware.
The complaint accuses Sanofi-Aventis of willful and deliberate infringement, while seeking attorney’s fees, as well as preliminary and permanent injunctions. Also named in...
To view the full article, register now.